<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264277</url>
  </required_header>
  <id_info>
    <org_study_id>PROLONG STUDY</org_study_id>
    <nct_id>NCT00264277</nct_id>
  </id_info>
  <brief_title>D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism</brief_title>
  <official_title>D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized &quot;Prolong&quot; Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <brief_summary>
    <textblock>
      The optimal duration of oral anticoagulant treatment in patients with idiopathic venous&#xD;
      thromboembolism is still uncertain. The present study addresses the possible role of the&#xD;
      D-dimer test in assessing the need for continuation of anticoagulation.The study aims at&#xD;
      assessing whether D-dimer assay may have a role in guiding the duration of anticoagulation in&#xD;
      these patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective follow-up study in patients with a first episode of&#xD;
      symptomatic idiopathic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary&#xD;
      embolism) who are treated with vitamin K antagonists (either warfarin or acenocoumarol) for a&#xD;
      minimum of 3 months. Eligible patients who give informed consent are instructed to&#xD;
      immediately stop oral anticoagulation and refrain from taking any other antithrombotic drugs&#xD;
      until the next visit, scheduled after 30 days. At that visit, venous blood is sampled to&#xD;
      perform D-dimer assay and thrombophilia tests. D-dimers are assessed using the Clearview&#xD;
      Simplify D-dimer assay (Agen Biomedical Limited, Brisbane, Australia). Patients with normal&#xD;
      D-dimer results do not continue anticoagulation, whereas those with elevated D-dimer results&#xD;
      are randomized using a computer program to either stop or resume anticoagulation with vitamin&#xD;
      K antagonists (INR 2.0-3.0). All patients are followed-up for 18 months. The study outcome&#xD;
      are the composite of confirmed recurrent venous thromboembolism and major bleeding events.&#xD;
      All suspected outcome events and all deaths are evaluated by a central adjudication committee&#xD;
      whose members are unaware of the D-dimer and thrombophilia results and of the group&#xD;
      assignments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed recurrent proximal deep vein thrombosis and/or pulmonary embolism at 18 months follow up</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed major bleeding events at 18 months follow up</measure>
  </primary_outcome>
  <enrollment>600</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist (Coumarin anticoagulants)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  After a first documented idiopathic proximal deep vein thrombosis and/or pulmonary&#xD;
             embolism&#xD;
&#xD;
          -  After at least 3 months of oral anticoagulation&#xD;
&#xD;
          -  After written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If the Venous thromboembolism occurred:&#xD;
&#xD;
          -  during pregnancy or puerperium&#xD;
&#xD;
          -  after recent (i.e. within three months) fracture or plaster casting of a leg,&#xD;
&#xD;
          -  after immobilization with confinement to bed for three consecutive days&#xD;
&#xD;
          -  after surgery with general anesthesia lasting longer than 30 minutes&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
          -  active cancer&#xD;
&#xD;
          -  antiphospholipid antibody syndrome&#xD;
&#xD;
          -  antithrombin deficiency&#xD;
&#xD;
          -  serious liver disease or renal insufficiency (creatininemia &gt; 2 mg/dL),&#xD;
&#xD;
          -  other indications for anticoagulation or contraindications for this treatment&#xD;
&#xD;
          -  limited life expectation&#xD;
&#xD;
          -  Patients who live too far from the clinical center&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GUALTIERO PALARETI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Dept. Angiology &amp; Blood Coagulation, University Hospital S. Orsola-Malpighi, Bologna, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Angiology &amp; Blood Coagulation, University Hospital S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002 Jan;87(1):7-12.</citation>
    <PMID>11848459</PMID>
  </reference>
  <reference>
    <citation>Palareti G, Legnani C, Cosmi B, Valdr√© L, Lunghi B, Bernardi F, Coccheri S. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003 Jul 22;108(3):313-8. Epub 2003 Jul 7.</citation>
    <PMID>12847064</PMID>
  </reference>
  <reference>
    <citation>Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003 Aug 27;290(8):1071-4.</citation>
    <PMID>12941680</PMID>
  </reference>
  <results_reference>
    <citation>Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006 Oct 26;355(17):1780-9. Erratum in: N Engl J Med. 2006 Dec 28;355(26):2797.</citation>
    <PMID>17065639</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>GUALTIERO PALARETI</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>D-dimer</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

